Skip to main content

Advertisement

SpringerLink
Log in

A Comprehensive Overview of the Hereditary Periodic Fever Syndromes

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Innate immunity is a critical partner in the regulation of inflammation and some mutations in genes implied in innate immunity pathways can cause genetic disorders characterized by seemingly unprovoked self-limited inflammatory attacks. These rare conditions are collectively named “hereditary periodic fever syndromes” (HPFS), and protean pathogenetic mechanisms combined with several clinical phenotypes characterize at least four distinct conditions: (1) familial Mediterranean fever, which is the prototype and the most widely recognized among HPFS, inherited as an autosomal recessive disorder showing recurrent dysregulated inflammatory processes, caused by an abnormal interaction between cytoskeleton and inflammasome, a key-signaling platform that releases interleukin-1β (IL-1β); (2) the group of cryopyrin-associated periodic syndrome, which upsets directly the production of IL-1β, with a dominant pattern of inheritance; (3) tumor necrosis factor receptor-associated periodic syndrome, which is an autosomal dominant disorder subverting the functions and traffic of a cell membrane protein; and (4) mevalonate kinase deficiency, which is an autosomal recessive metabolic disorder halting the biosynthesis of cholesterol. MEFV, NLRP3, TNFRSF1A, and MVK are respectively the four causing genes of these conditions, all resulting in excessive IL-1β signaling, though the encoded proteins act at different levels in cytoskeletal filament organization, apoptosis, and activation of the IL-1β-structured inflammasome. The differential diagnosis of HPFS can be challenging, as there are no universally accepted diagnostic algorithms, and near half of patients may have a specific disease without any genetic pathogenetic variant identified. Herein, we outline the most relevant aspects of HPFS at the crossroads between clinical medicine and immunology and all the most recent advances in their treatment, as the increasing use of IL-1 antagonists has achieved unexpected clinical results in a large number of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cooper EL (2010) Evolution of immune systems from self/not self to danger to artificial immune systems (AIS). Phys Life Rev 7(1):55–78. doi:10.1016/j.plrev.2009.12.001

    Article  PubMed  Google Scholar 

  2. Dzik JM (2010) The ancestry and cumulative evolution of immune reactions. Acta Biochim Pol 57(4):443–466

    PubMed  CAS  Google Scholar 

  3. Buchmann K (2014) Evolution of innate immunity: clues from invertebrates via fish to mammals. Front Immunol 23(5):459. doi:10.3389/fimmu.2014.00459

    Article  CAS  Google Scholar 

  4. Rigante D, Lopalco G, Vitale A et al (2014) Untangling the web of systemic autoinflammatory diseases. Mediat Inflamm 2014:948154. doi:10.1155/2014/948154

    Article  CAS  Google Scholar 

  5. Aksentijevich I, Kastner DL (2011) Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol 7(8):469–478. doi:10.1038/nrrheum.2011.94

    Article  PubMed  CAS  Google Scholar 

  6. Lamkanfi M, Dixit VM (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28:137–161. doi:10.1146/annurev-cellbio-101011-155745

    Article  PubMed  CAS  Google Scholar 

  7. Cantarini L, Lopalco G, Cattalini M, Vitale A, Galeazzi M, Rigante D (2015) Interleukin-1: ariadne’s thread in autoinflammatory and autoimmune disorders. Israel Med Assoc J 17(2):93–97

    Google Scholar 

  8. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA (1984) Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A 81(24):7907–7911

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Mariathasan S, Monack DM (2007) Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7(1):31–40

    Article  PubMed  CAS  Google Scholar 

  10. Vitale A, Rigante D, Lucherini OM et al (2013) Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm 2013:939847. doi:10.1155/2013/939847

    Article  CAS  Google Scholar 

  11. Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet 351(9103):659–664

    Article  PubMed  CAS  Google Scholar 

  12. Centola M, Wood G, Frucht DM et al (2000) The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95(10):3223–3231

    PubMed  CAS  Google Scholar 

  13. Touitou I, Lesage S, McDermott M et al (2004) Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat 24(3):194–198. doi:10.1002/humu.20080

    Article  PubMed  CAS  Google Scholar 

  14. Rigante D, Vitale A, Lucherini OM, Cantarini L (2014) The hereditary autoinflammatory disorders uncovered. Autoimmun Rev 13(9):892–900. doi:10.1016/j.autrev.2014.08.001

    Article  PubMed  CAS  Google Scholar 

  15. Balci B, Tinaztepe K, Yilmaz E et al (2002) MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study. Nephrol Dial Transplant 17(11):1921–1923

    Article  PubMed  CAS  Google Scholar 

  16. Bilginer Y, Akpolat T, Ozen S (2011) Renal amyloidosis in children. Pediatr Nephrol 26(8):1215–1227. doi:10.1007/s00467-011-1797-x

    Article  PubMed  PubMed Central  Google Scholar 

  17. Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885

    Article  PubMed  CAS  Google Scholar 

  18. Jéru I, Hentgen V, Cochet E et al (2013) The risk of familial Mediterranean fever in MEFV heterozygotes: a statistical approach. PLoS One 8(7):e68431. doi:10.1371/journal.pone.0068431

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Marek-Yagel D, Berkun Y, Padeh S et al (2009) Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum 60(6):1862–1866. doi:10.1002/art.24570

    Article  PubMed  CAS  Google Scholar 

  20. Rigante D, La Torraca I, Avallone L, Pugliese AL, Gaspari S, Stabile A (2006) The pharmacological basis of treatment with colchicine in children with familial Mediterranean fever. Eur Rev Med Pharmacol Sci 10(4):173–178

    PubMed  CAS  Google Scholar 

  21. Rigante D, Frediani B, Galeazzi M, Cantarini L (2013) From the Mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases. Biomed Res Int 2013:485103. doi:10.1155/2013/485103

    Article  PubMed  PubMed Central  Google Scholar 

  22. Aksentijevich I, Galon J, Soares M et al (2001) The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 69(2):301–314

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Caso F, Cantarini L, Lucherini OM et al (2014) Working the endless puzzle of hereditary autoinflammatory disorders. Mod Rheumatol 24(3):381–389. doi:10.3109/14397595.2013.843755

    Article  PubMed  CAS  Google Scholar 

  24. Cantarini L, Rigante D, Merlini G et al (2014) The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum 43(6):818–823. doi:10.1016/j.semarthrit.2013.12.002

    Article  PubMed  CAS  Google Scholar 

  25. Savic S, Dickie LJ, Wittmann M, McDermott MF (2012) Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Pract Res Clin Rheumatol 26(4):505–533. doi:10.1016/j.berh.2012.07.009

    Article  PubMed  CAS  Google Scholar 

  26. Rigante D, Lopalco G, Vitale A et al (2014) Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clin Rheumatol 33(9):1197–1207. doi:10.1007/s10067-014-2722-z

    Article  PubMed  Google Scholar 

  27. Stojanov S, McDermott MF (2005) The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 7(22):1–18

    Article  PubMed  Google Scholar 

  28. Rigante D, Cantarini L, Imazio M et al (2011) Autoinflammatory diseases and cardiovascular manifestations. Ann Med 43(5):341–346. doi:10.3109/07853890.2010.547212

    Article  PubMed  CAS  Google Scholar 

  29. Ravet N, Rouaghe S, Dodé C et al (2006) Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 65(9):1158–1162

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Aksentijevich I, D Putnam C, Remmers EF et al (2007) The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 56(4):1273–1285

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Cantarini L, Lucherini OM, Frediani B et al (2011) Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes. Int J Immunopathol Pharmacol 24(4):827–836

    Article  PubMed  CAS  Google Scholar 

  32. Tanaka N, Izawa K, Saito MK et al (2011) High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum 63(11):3625–3632. doi:10.1002/art.30512

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Hoffman HM, Wanderer AA, Broide DH (2001) Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108(4):615–620

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Aganna E, Martinon F, Hawkins PN et al (2002) Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46(9):2445–2452

    Article  PubMed  CAS  Google Scholar 

  35. Prieur AM, Griscelli C, Lampert F et al (1987) A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol 66:57–68

    Article  CAS  Google Scholar 

  36. Rigante D (2010) The protean visage of systemic autoinflammatory syndromes: a challenge for inter-professional collaboration. Eur Rev Med Pharmacol Sci 14(1):1–18

    PubMed  CAS  Google Scholar 

  37. Esposito S, Ascolese B, Senatore L et al (2014) Current advances in the understanding and treatment of mevalonate kinase deficiency. Int J Immunopathol Pharmacol 27(4):491–498

    Article  PubMed  CAS  Google Scholar 

  38. Mendey SH, Kuijk LM, Frenkel J, Waterham HR (2006) A role for geranylgeranylation in interleukin-1β secretion. Arthritis Rheum 54(11):3690–3695

    Article  CAS  Google Scholar 

  39. Mendey SH, Schneiders MS, Koster J, Waterham HR (2006) Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Hum Mutat 27(8):796–802

    Article  CAS  Google Scholar 

  40. van der Burgh R, ter Haar NM, Boes ML, Frenkel J (2013) Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol 147(3):197–206. doi:10.1016/j.clim.2012.09.011

    Article  PubMed  CAS  Google Scholar 

  41. Berody S, Galeotti C, Koné-Paut I, Piram M (2015) A restrospective survey of patients journey before the diagnosis of mevalonate kinase deficiency. Joint Bone Spine 82(4):240–244. doi:10.1016/j.jbspin.2014.12.011

    Article  PubMed  Google Scholar 

  42. Bader-Meunier B, Florkin B, Sibilia J et al (2011) Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics 128(1):e152–159. doi:10.1542/peds.2010-3639

    Article  PubMed  Google Scholar 

  43. Ammouri W, Cuisset L, Rouaghe S et al (2007) Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology (Oxford) 46(10):1597–1600

    Article  CAS  Google Scholar 

  44. Rigante D, Emmi G, Fastiggi M, Silvestri E, Cantarini L (2015) Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clin Rheumatol 34(8):1333–1339. doi:10.1007/s10067-015-2923-0

    Article  PubMed  Google Scholar 

  45. Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A (2003) The contribution of genotypes at the MEFV and SSA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48(4):1149–1155

    Article  PubMed  Google Scholar 

  46. Ben-Zvi I, Livneh A (2011) Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 7(2):105–112. doi:10.1038/nrrheum.2010.181

    Article  PubMed  CAS  Google Scholar 

  47. Hentgen V, Grateau G, Kone-Paut I et al (2013) Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum 43(3):387–391. doi:10.1016/j.semarthrit.2013.04.011

    Article  PubMed  Google Scholar 

  48. Roldan R, Ruiz AM, Miranda MD, Collantes E (2008) Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine 75(4):504–505. doi:10.1016/j.jbspin.2008.04.001

    Article  PubMed  Google Scholar 

  49. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Koné-Paut I (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41(2):265–271. doi:10.1016/j.semarthrit.2010.11.003

    Article  PubMed  CAS  Google Scholar 

  50. Bulua AC, Mogul DB, Aksentijevich I et al (2012) Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 64(3):908–913. doi:10.1002/art.33416

    Article  PubMed  CAS  Google Scholar 

  51. Nedjai B, Hitman GA, Quillinan N et al (2009) Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 60(2):619–625. doi:10.1002/art.24294

    Article  PubMed  CAS  Google Scholar 

  52. Grimwood C, Despert V, Jeru I, Hentgen V (2015) On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Rheumatology (Oxford) 54(9):1749–1751. doi:10.1093/rheumatology/kev111

    Article  Google Scholar 

  53. Federico G, Rigante D, Pugliese A, Ranno O, Catania S, Stabile A (2003) Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand J Rheumatol 32(5):312–314

    Article  PubMed  CAS  Google Scholar 

  54. Koné-Paut I, Galeotti C (2014) Anakinra for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol 10(1):7–18. doi:10.1586/1744666X.2014.861325

    Article  PubMed  CAS  Google Scholar 

  55. Rigante D, Ansuini V, Caldarelli M, Bertoni B, La Torraca I, Stabile A (2006) Hydrocephalus in CINCA syndrome treated with anakinra. Childs Nerv Syst 22(4):334–337

    Article  PubMed  CAS  Google Scholar 

  56. Kuemmerle-Deschner JB, Hachulla E, Cartwright R et al (2011) Two-years results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70(12):2095–2102. doi:10.1136/ard.2011.152728

    Article  PubMed  CAS  Google Scholar 

  57. Blech M, Peter D, Fischer P et al (2013) One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. J Mol Biol 425(1):94–111. doi:10.1016/j.jmb.2012.09.021

    Article  PubMed  CAS  Google Scholar 

  58. Lachmann HJ, Koné-Paut I, Kuemmerle-Deschner JB et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360(23):2416–2425. doi:10.1056/NEJMoa0810787

    Article  PubMed  CAS  Google Scholar 

  59. Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB et al (2011) Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 13:R202. doi:10.1186/ar3535

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Anton J, Calvo I, Fernández-Martin J et al (2015) Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort. Clin Exp Rheumatol 33(6 Suppl 94):S67–71

    PubMed  Google Scholar 

  61. Steichen O, van der Hilst J, Simon A, Cuisset L, Grateau G (2009) A clinical criterion to exclude the hyperimmunoglobulin D syndrome (mild mevalonate kinase deficiency) in patients with recurrent fever. J Rheumatol 36(8):1677–1681. doi:10.3899/jrheum.081313

    Article  PubMed  Google Scholar 

  62. Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A, Frenkel J (2011) On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 70(12):2155–2158. doi:10.1136/ard.2011.149922

    Article  PubMed  CAS  Google Scholar 

  63. Galeotti C, Meinzer U, Quartier P et al (2012) Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) 51(10):1855–1859

    Article  CAS  Google Scholar 

  64. Neven B, Valayannopoulos V, Quartier P et al (2007) Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med 356(26):2700–2703

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pediatrics, Periodic Fever Research Center, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica Sacro Cuore, Rome, Italy

    Donato Rigante

  2. Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

    Bruno Frediani & Luca Cantarini

Authors
  1. Donato Rigante
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruno Frediani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luca Cantarini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luca Cantarini.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rigante, D., Frediani, B. & Cantarini, L. A Comprehensive Overview of the Hereditary Periodic Fever Syndromes. Clinic Rev Allerg Immunol 54, 446–453 (2018). https://doi.org/10.1007/s12016-016-8537-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-016-8537-8

Keywords

Search

Navigation